You are here: Home > Prescription(RX) Drugs > R > Re Nata Ob (River's Edge Pharmaceuticals, Llc)|
RE NATA OB
cupric oxide and
magnesium oxide tablet
Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
----------RE-Nata 29 OB Prenatal Vitamin Tablets
INACTIVE INGREDIENTS:RE-Nata 29 OB Prenatal Vitamins Tablets also contain carnauba wax, croscarmellose sodium, dicalcium phosphate, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, stearic acid, titanium dioxide.
INDICATIONS AND USAGE:RE-Nata 29 OB Prenatal Vitamin Tablets are indicated to provide vitamin and mineral supplementation throughout pregnancy and during postnatal period for the lactating and non-lactating mother. It is also useful for improving the nutritional status prior to conception.
RE-Nata 29 OB Prenatal Vitamin Tablets contain 1 mg folic acid, which is very important in the development of the baby’s spinal column, especially during the first trimester. Women are advised to start taking folate supplementation several weeks before conception and to continue taking them through the first 12 weeks of pregnancy, or longer. It is recommended that all women of childbearing years take supplements containing folic acid.
RE-Nata 29 OB Prenatal Vitamin Tablets are contraindicated in patients with known hypersensitivity to any of its ingredients. Folic acid (pteroylglutamic acid) is contraindicated in patients with untreated and uncomplicated pernicious anemia, and in those with anaphylactic sensitivity to folic acid. Iron therapy is contraindicated in patients with hemochromatosis and patients with iron storage disease or the potential for iron storage disease due to chronic hemolytic anemia (e.g., inherited anomalies of hemoglobin structure or synthesis and/or red cell enzyme deficiencies, etc.), pyridoxine responsive anemia or cirrhosis of the liver.
Pernicious anemia should be ruled out before starting treatment. While folic acid corrects the hematological profile of pernicious anemia, it does not ameliorate the underlying neurologic involvement.
General: Before prescribing to patients with kidney stones, the calcium content should be considered. Folic acid may partially correct the hematological damage due to deficiency of pernicious anemia, while the associated neurological damage progresses. In rare instances allergic sensitization has been reported following both oral and parenteral administration of folic acid.
Allergic sensitivity reactions and gastrointestinal disturbances may occur. By taking RE-Nata 29 OB Prenatal Vitamin Tablets shortly after meals, G.I. disturbances may be controlled.
RE-Nata 29 OB Prenatal Vitamin Tablets are supplied as round, white tablets, debossed with “RE 394,” in bottles of 90 tablets (NDC # 68032-394-90). Dispense in a tight, light-resistant container with a child resistant closure as defined by the USP.
Store at controlled room temperature 15°–30°C (59°–86°F). Protect from moisture and excessive heat.
Revised: 04/2011 River's Edge Pharmaceuticals, LLC
Reproduced with permission of U.S. National Library of Medicine
Copyright © 2017
|Over-the-counter (OTC) Drugs|